Department of Neurological Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-0012, Japan.
J Clin Neurosci. 2011 Jul;18(7):895-8. doi: 10.1016/j.jocn.2010.10.020. Epub 2011 May 11.
We analyzed the factors that affect the long-term clinical outcome of a series of patients with skull base meningiomas. Clinical records of 73 patients with cranial base meningiomas were reviewed retrospectively, of whom 13 patients experienced a recurrence at various times following the initial surgery. The mean follow-up time was 90.4 ± 21.2 months (range=60-124 months). Based on the location of the recurrence, patients with recurrence were divided into peripheral (n=6) and central (n=7) skull base groups. Of several variables analyzed using a multivariate logistic regression model, "high MIB-1 (Ki-67 proliferation antigen) labeling index" was an independent variable predicting poor long-term functional outcomes. Recurrence of the tumor at the central skull base was also a strong predictor of poor long-term outcomes. An increased proliferative potential, as indicated by a high MIB-1 labeling index, may induce repeated recurrences, eventually leading to worse functional outcomes, particularly for patients with central skull base meningiomas.
我们分析了一系列颅底脑膜瘤患者长期临床结局的影响因素。回顾性分析了 73 例颅底脑膜瘤患者的临床资料,其中 13 例患者在初次手术后的不同时间复发。平均随访时间为 90.4 ± 21.2 个月(范围为 60-124 个月)。根据复发部位,将复发患者分为外周(n=6)和中央(n=7)颅底组。使用多变量逻辑回归模型分析了几个变量,其中“高 MIB-1(Ki-67 增殖抗原)标记指数”是预测长期功能结局不良的独立变量。中央颅底肿瘤的复发也是长期结局不良的强烈预测因素。高 MIB-1 标记指数表明增殖潜能增加,可能导致反复复发,最终导致功能结局更差,尤其是对于中央颅底脑膜瘤患者。